{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 33,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a line chart showing HCQN subscale scores over time and a two-stage clinical trial design diagram.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/29",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.32,
        "w": 0.6,
        "x": 0.37,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Prior evidence in humans (third party study) showing HCQN subscale scores over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8778cb7-c21c-42f4-83dd-428ce1f38d58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.6,
        "x": 0.37,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Ongoing Phase 1/2 trial: Stage 1 (Max Tolerated Dose) and Stage 2 (Proof of Concept)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f726730-b2e9-4740-981a-4225f71f3f4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.37,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: HCQN = Heroin Craving Questionnaire, PK = Pharmacokinetics. 1. Ownership percentage... 2. Mash et al., 'Ibogaine Detoxification...'",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "775437df-2d8a-4c2c-a6fd-035c089adc7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.33,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "table",
      "text": "Ownership: 59.5%, Product: Ibogaine HCl capsules, Pharmacology: Receptor modulator, Product Features: Rapid withdrawal, Indications: Opioid Use Disorder, Status: Phase 1/2, IP: Pending, Highlight: Sustained reduction",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ee14664-5077-46e1-82dc-a810b516a19e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.6,
        "x": 0.37,
        "y": 0.07
      },
      "kind": "title",
      "text": "A single-dose of ibogaine showed potential for sustained reductions in opioid cravings in 75 opioid-dependent patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "580c8a87-2095-404a-a8b7-4d647dceecf7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.13,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09e5c841-9fea-4905-bfaf-f2eff780f211",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e4e3614b-d30b-4eaa-a0f7-c5def27255ed",
      "evidence": "The slide title is 'SUMMARY' and presents a summary of a study on ibogaine for opioid use disorder.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 29,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "881a7577-25cc-41b7-b2fe-88ebe2283b82",
      "evidence": "The deck presents a sense of urgency, highlighting the potential for growth and innovation in the mental health space.",
      "position": 1,
      "objective": "Explain why now is the right time for atai Life Sciences' solutions",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}